triazoles has been researched along with bortezomib in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 12 (48.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaplow, R | 1 |
| Scheinfeld, N | 1 |
| Abe, M; Fujii, S; Harada, T; Jinno, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K; Yata, K | 1 |
| Hashimoto, N; Hattori, Y; Kato, J; Koda, Y; Mori, T; Okamoto, S; Sadahira, K; Shimizu, T; Tsukada, Y; Yamane, A; Yokoyama, K | 1 |
| Belitsky, G; Budunova, I; Gordon, LI; Kirsanov, K; Lesovaya, E; Popa, A; Rosen, ST; Yakubovskaya, M; Yemelyanov, A | 1 |
| McNeil, C | 1 |
| Bertino, JR; Bhagavathi, S; Johnson-Farley, N; Veliz, J | 1 |
| Aboukameel, A; Argueta, C; Azmi, AS; Drolen, C; Kashyap, T; Kauffman, M; Klebanov, B; Landesman, Y; Lee, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Unger, TJ | 1 |
| Bauer, AA; Dai, Y; Dawson, JL; Gomez, J; Grant, S; Kashyap, T; Landesman, Y; Meads, M; Shain, KH; Sullivan, DM; Turner, JG | 1 |
| Chen, W; Cui, L; Fang, S; Hou, X; Huang, YY; Li, HQ; Liu, CY; Ouyang, X; Wang, G; Wu, T; Yang, Y; Yu, T; Zhong, Y | 1 |
| Chen, W; Cui, L; Du, P; Huang, Y; Huang, Z; Liu, CY; Liu, Y; Wang, G; Wu, T; Yang, Y; Zhu, Z | 1 |
| Gourd, E | 1 |
| Abruzzese, MP; Bilotta, MT; Cippitelli, M; Fionda, C; Molfetta, R; Paolini, R; Petrucci, MT; Ricciardi, MR; Santoni, A; Soriani, A; Zingoni, A | 1 |
| Dakle, P; Jeitany, M; Jiang, YY; Kanojia, D; Kappei, D; Koeffler, HP; Landesman, Y; Madan, V; Mukundan, V; Pathak, E; Prabhu, A; Tam, WL | 1 |
| Avigdor, A; Geva, M; Magen, H; Nagler, A; Volchik, Y | 1 |
| Chari, A; Cho, HJ; DeCastro, A; Jagannath, S; Landesman, Y; Madduri, D; Mouhieddine, TH; Parekh, S; Richter, J; Shah, J | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, AZ; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hájek, R; Jagannath, S; Jeha, J; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Delimpasi, S; Dimopoulos, MA; Grosicki, S; Kauffman, MG; Moreau, P; Richardson, PG | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Chang, H; Chari, A; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Facon, T; Garg, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Landesman, Y; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richard, S; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Bar, N; Di, M; Giri, S; Huntington, SF; Parker, T; Patel, KK | 1 |
| Anderson, LD; Auner, HW; Bahlis, NJ; Beaumont, JL; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Facon, T; Garg, MK; Grosicki, S; Hájek, R; Hudgens, S; Illmer, T; Jagannath, S; Kauffman, M; Kriachok, I; Leleu, X; Leong, H; Levy, M; Ma, X; Pour, L; Quach, H; Richardson, P; Sanchez, L; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Tang, S; Usenko, G; Venner, C; Yu, H | 1 |
| Dolph, M; Leong, H; Tremblay, G | 1 |
| Arazy, M; Auner, HW; Benjamin, R; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Garg, MK; Gavriatopoulou, M; Grosicki, S; Hájek, R; Kauffman, MG; Leleu, X; Levy, Y; Mateos, MV; Moreau, P; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Sinha, DK; Venner, CP | 1 |
| Ben-Shahar, O; Cass, M; Kashyap, T; Landesman, Y; McDonald, AB | 1 |
2 review(s) available for triazoles and bortezomib
| Article | Year |
|---|---|
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles | 2007 |
3 trial(s) available for triazoles and bortezomib
| Article | Year |
|---|---|
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cytogenetic Analysis; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Treatment Outcome; Triazoles; Young Adult | 2021 |
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Triazoles | 2021 |
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrazines; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Survival Rate; Triazoles | 2022 |
20 other study(ies) available for triazoles and bortezomib
| Article | Year |
|---|---|
[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Topics: Acidosis; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Male; Micafungin; Multiple Myeloma; Pyrazines; Pyrimidines; Triazoles; Tumor Lysis Syndrome; Voriconazole; Zygomycosis | 2010 |
[Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Topics: Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Drug Therapy, Combination; Humans; Intestinal Pseudo-Obstruction; Itraconazole; Middle Aged; Multiple Myeloma; Mycoses; Pyrazines; Pyrimidines; Triazoles; Voriconazole | 2012 |
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Dexamethasone; Dimerization; Drug Synergism; Hematologic Neoplasms; Humans; K562 Cells; Lymphoma; NF-kappa B; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Receptors, Glucocorticoid; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1; Transcriptional Activation; Triazoles; Tumor Cells, Cultured | 2013 |
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Cyclohexanes; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Immunosuppressive Agents; Maraviroc; Methotrexate; Pentostatin; Peripheral Blood Stem Cell Transplantation; Pyrazines; Quality of Life; Tacrolimus; Triazoles; Vorinostat | 2013 |
ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azepines; Biomimetics; Blotting, Western; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Humans; Lymphoma; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2015 |
Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bortezomib; Cell Death; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Female; Fibrosarcoma; Humans; Hydrazines; Karyopherins; Mice, Inbred ICR; Mice, SCID; NF-kappa B; NF-KappaB Inhibitor alpha; Osteosarcoma; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Signal Transduction; Time Factors; Transcription Factor RelA; Transfection; Triazoles | 2016 |
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Oligopeptides; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Time Factors; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Nucleus; Cell Survival; Colorectal Neoplasms; Drug Synergism; HCT116 Cells; HeLa Cells; Humans; Hydrazines; Mice; Proteasome Inhibitors; Triazoles; Tumor Suppressor Protein p53; Ubiquitination; Xenograft Model Antitumor Assays | 2017 |
Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Topics: Animals; Antineoplastic Agents; Azepines; Bortezomib; Cell Cycle Checkpoints; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; NF-kappa B; Nuclear Proteins; Oncogene Protein p55(v-myc); Proto-Oncogene Proteins c-myc; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Promising new treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Humans; Hydrazines; Multiple Myeloma; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2018 |
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Azepines; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Genes, Homeobox; Homeodomain Proteins; Humans; Immunomodulation; Multiple Myeloma; Protein Domains; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases | 2019 |
Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Fatty Acid Desaturases; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Liposarcoma; Oligopeptides; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Triazoles | 2020 |
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Female; Frailty; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Triazoles | 2021 |
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Triazoles | 2021 |
Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply.
Topics: Bortezomib; Boston; Control Groups; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2021 |
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Triazoles | 2021 |
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Boston; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |